RE: Vivaglobin

[Marilyn Hanchett]

SCIG has been done successfully with PID patients for years. It originated in Europe and a lit search will produce a fairly comprehensive review of the procedures, rates and associated outcomes. Since the SCIG procedure usually requires weekly administration, it is a viable option for those individuals who 1) do not want to miss work/school in order to receive IVIG in a more traditional setting and 2) are motivated to assume responsibility for self administration.. It is also popular choice in peds.   In Europe, SCIG is done using a 16% product. A similar product has not been available in the US, so providers have usually opted for a 10% product. The new ZLB Behring product, Vivaglobulin, will be the first 16% SCIG in the US.  Due to competition within the specialty pharmacy arena, your best & most readily available resources to learn more are a review of the published literature, support from the manufacturer, and the Immune Deficiency Foundation, as they have been investigating SCIG for years and offered a session on it at their national conference last year.   M Hanchett RN Director of Clinical Affairs IgG America From: [EMAIL PROTECTED] [mailto:[EMAIL PROTECTED] On Behalf Of KayBeth Weibel, CRNI Sent: Monday, March  06, 2006 1:18 PM To: [EMAIL PROTECTED] Subject: Vivaglobin Hello,   I received notice today from the FDA of approval for “First Immune Globulin for Subcutaneous use”, Vivaglobin.  I have not administered IG subcutaneously before.  Does anybody have any experiences or comments?   Thanks   KayBeth Weibel, RN, CRNI Director of Nursing Services Infusion Network Falmouth, MA 02540 tel (508) 548-4266 fax (508) 540-7549